- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma
June 4th 2022, 11:25pm
Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.
SOT101 Displays Antitumor Activity Alone and With Pembrolizumab in Advanced Solid Tumors
June 4th 2022, 11:20pm
SOT101 alone and in combination with pembrolizumab demonstrated a favorable safety profile with no additional toxicities reported and promising efficacy among patients with advanced solid tumors, according to findings from the phase 1 AURELIO-03 trial.
Palbociclib Plus Letrozole Misses OS End Point in ER+/HER2- Advanced Breast Cancer
June 4th 2022, 11:10pm
First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.
Trastuzumab Deruxtecan Remains Safe and Effective Option for Metastatic Breast Cancer
June 4th 2022, 11:05pm
Updated data from a safety analysis of the phase 3 DESTINY-Breast03 study confirmed the tolerability of trastuzumab deruxtecan among patients with with HER2-positive unresectable or metastatic breast cancer.
Epcoritamab Plus R2 Elicits High Metabolic Response Rate in Relapsed/Refractory Follicular Lymphoma
June 4th 2022, 10:50pm
The addition of subcutaneous epcoritamab to treatment with rituximab and lenalidomide resulted in a 100% response rate and a low incidence of low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, according to findings from arm 2 of the EPCORE NHL-2 trial.
Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory AML and MPNs
June 4th 2022, 10:25pm
Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
Patritumab Deruxtecan Induces Promising Efficacy in HER3-Expressing Metastatic Breast Cancers
June 4th 2022, 10:25pm
Patritumab deruxtecan produced encouraging responses in patients with HER3-expressing metastatic breast cancer or metastatic triple negative breast cancer.
Dr. Falchi on the Use of Epcoritamab with R-CHOP Therapy in High-Risk DLBCL
June 4th 2022, 10:21pm
Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.
ctDNA Demonstrates Efficacy as Treatment-Decision Tool for Adjuvant Chemotherapy in Colon Cancers
June 4th 2022, 8:15pm
Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.
Long-Term Follow-Up Supports Acalabrutinib-Based Regimens in Treatment-Naïve CLL
June 4th 2022, 7:50pm
At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors
June 4th 2022, 7:30pm
BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.
Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL
June 4th 2022, 6:30pm
The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.
Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS
June 4th 2022, 5:55pm
Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).
Hyper-CVAD Plus Sequential Blinatumomab With or Without Inotuzumab Elicits Clinical Benefit in Ph-Negative B-Cell ALL
June 4th 2022, 5:30pm
Sequential administration of blinatumomab with or without inotuzumab following hyper-CVAD elicited high rates of minimal residual disease negativity and a durable overall survival benefit among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic lymphoma.
Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML
June 4th 2022, 5:30pm
The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.
Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma
June 4th 2022, 5:15pm
Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.
Sacituzumab Govitecan Demonstrates Significant Clinical Benefit in HR+/HER2- Metastatic Breast Cancer
June 4th 2022, 4:30pm
Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.
Pacritinib Offers Safe and Tolerable Treatment Option for Patients With Myelofibrosis
June 4th 2022, 3:30pm
Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.
Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC
June 4th 2022, 2:45pm
Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.
Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer
June 4th 2022, 1:10pm
Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.